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Abstract
Due to its strong proliferation-reducing effects on keratinocytes, and also anti-inflammatory
properties, the isoflavone genistein has already been proposed as a possible antipsoriatic
compound. As there is still no detailed information on this topic, we examined the effects of
genistein by using an in vitro model of both, normal and “psoriasis-like” keratinocytes at this
stage of our work exhaustively testing the selected flavonoid in a mono-treated experimental
design. Gene expression studies revealed transcriptional changes that confirms known dis-
ease-associated pathways and highlights many psoriasis-related genes. Our results sug-
gested that aberrant expression of genes contributing to the progress of psoriasis could be
improved by the action of genistein. Genistein prevented “cytokine mix” as well as TNF-α-
induced NF-κB nuclear translocation, with no effect on the PI3K signaling cascade, indicat-
ing the luck of turning this pathway into NF-κB activation. It could have attenuated TNF-α
and LPS-induced inflammatory responses by suppressing ROS activation. Regardless of
the type of keratinocyte stimulation used, reduction of cytokine IL-8, IL-20 and CCL2 produc-
tion (both at RNA and protein level) following genistein treatment was visible. Because
investigations of other groups supported our commentary on potential administration of
genistein as a potential weapon in the armamentarium against psoriasis, it is believed that
this paper should serve to encourage researchers to conduct further studies on this subject.
Introduction
A broad spectrum of natural compounds is routinely applied in the daily diet of many patients
with no information about possible mechanisms of their actions. Such agents with anti-inflam-
matory activities are applied all over the world as alternative medicines for psoriasis (Ps)
because of their perceived beneficial impact on the skin. Although many treatments are avail-
able to reduce the bothersome symptoms and appearance of psoriasis, it continues to remain
incurable, and its cause stays unelucidated. Within the last decade, substantial advances have
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been made in clarifying the molecular pathogenesis of psoriasis. Transcriptomic analyses have
been widely used in recent years to identify differentially expressed genes (DEGs) associated
with psoriasis pathology [1–6]. While there is now increasing insight into the genes conferring
disease susceptibility, much less is known about the types of regulatory networks of expressed
genes that define the molecular signature of the disease. Besides important mRNA expression
alterations, Ps is also characterized by a specific microRNA expression profile, distinct from
that of healthy skin [7]. In addition, the meta-analysis produced a reference list of consistent
candidate genes for further investigation of psoriasis pathology and new therapeutic target
selection with the use of genetic markers [4].
Genistein (4,5,7-trihydroxyisoflavone) is a naturally occurring plant compound that exhib-
its multidirectional biological action. It displays antioxidant, antiproliferative, proapoptotic,
antiangiogenic, as well as estrogenic and anti-estrogenic activity. Ito’s group [8] investigated
topical application of Glyteer (GL, soybean) on a psoriatic model in mice. This isoflavone has
also attracted attention as a potent agent in the treatment of Ps [9, 10] not only due to its anti-
proliferative and immunosuppressive properties but also as a mediator modulating expression
of various genes whose products are involved among others in different phases of inflamma-
tion and proliferation [11]. However, the explicit mechanism of genistein’s action, especially
in human epithelial cells, is still not elucidated. Thus, we examined the effects of genistein on
activated spontaneously immortalized human keratinocytes, “psoriasis-like” HaCaT cell line,
to find new potential targets for therapy and/or to develop a tool for treatment. Despite being
limited by the lack of many of the cellular players in psoriasis, including fibroblasts and inflam-
matory cells, our monolayer in vitro model of “psoriasis-like” HaCaT has proved to be a valu-
able first step model system in the evaluation of nutraceutical agents such as genistein for Ps
improvement [12–16]. Our results suggest that the aberrant expression of genes contributing
to the progression of Ps can be improved by the action of genistein; they also explain in detail
the effects of this isoflavone on signaling cascades in the human epithelial cell line HaCaT.
Materials and methods
Cell lines, culture media and reagents
Spontaneously immortalized human keratinocytes (HaCaT cell line) were purchased from the
CLS Cell Lines Service GmbH (Eppelheim, Germany) [17]. HaCaT cells from passages 35–50
were maintained in Roswell Park Memorial Institute 1640 medium (RPMI 1640, Gibco,
Thermo Fisher Scientific, Bleiswijk, Netherlands) supplemented with 10% fetal bovine serum
(FBS, Gibco, Thermo Fisher Scientific, Bleiswijk, Netherlands) and 1% antibiotic/antimycotic
solution (Gibco, Thermo Fisher Scientific, Bleiswijk, Netherlands) at 37˚C in a humidified
atmosphere containing 5% carbon dioxide (CO2). THP-1 cells (CLS Cell Lines Service GmbH)
were routinely maintained in RPMI 1640 medium supplemented with 2 mM glutamine
(Gibco, Thermo Fisher Scientific, Bleiswijk, Netherlands) and 10% FBS (Gibco, Thermo Fisher
Scientific, Bleiswijk, Netherlands) at 2–8 x 105 cells/mL. Genistein was synthetized at the Phar-
maceutical Research Institute (Warsaw, Poland). The flavonoid was dissolved in dimethyl sulf-
oxide (DMSO, Sigma-Aldrich, St. Louis, USA) and added in the indicated final concentrations
as determined in previous studies [18, 19] to cell cultures. Methotrexate (MTX) was purchased
from Sigma-Aldrich (St. Louis, USA). It was dissolved in DMSO and added in the indicated
final concentrations [20].
Cell-viability assays
Cell viability was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. For cell cytotoxic assay and proliferation assay, 1.25 x 104 or 103 HaCaT cells,
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respectively, were seeded per well in 96-well culture plates and incubated overnight. Growth
medium was then substituted with fresh medium supplemented with tested compounds at
appropriate concentrations or 0.05% DMSO as a control (in cultures with tested compounds,
DMSO final concentration was also adjusted to 0.05%). Following incubation for 24 and 48
hours (to test cytotoxicity) or for 7 -days (to test cell proliferation), medium was substituted
with MTT solution (1 mg/mL in RPMI 1640 medium, Sigma-Aldrich, St. Louis, USA); and
after a 2-hour incubation at 37˚C the formazan product was dissolved in DMSO and absor-
bance was read at 550 nm (VICTOR Multilabel Plate Reader, PerkinElmer). The optical den-
sity of formazan formed in the control was taken as 100% of cell viability. Samples were
measured in quintuplicate, and the experiment was repeated three times. LC (cytotoxicity
assay) and IC (proliferation assay) index values of genistein was determined for each com-
pound in comparison to non-treated cultures (incubated with DMSO only).
Two-dimensional (2D) engineered skin psoriatic cells model development
Direct psoriatic stimulation. HaCaT cells were cultured to 80% of confluence in flasks
containing RPMI medium supplemented with 10% FBS and 1% antibiotic/antimycotic solu-
tion and then the cells were disaggregated using 0.025% trypsin with 0.01% EDTA. Cells were
seeded at a density of 4 x 105 cells/well in 6-well plates in defined serum-free defined keratino-
cyte medium (Keratinocyte-SFM, Gibco, Thermo Fisher Scientific, CA, USA) supplemented
with a pituitary extract including insulin (BPE) and epidermal growth factor (EGF) (Gibco,
Thermo Fisher Scientific, CA, USA). After a 24-hour incubation cells were cultivated in
serum-free keratinocyte medium without growth supplements for 16 hours. For further exper-
iments, cells were stimulated with a combination of a proinflammatory “cytokine mix”: IL-1A,
IL-17A, IL-22, oncostatin M (OSM), and tumor necrosis factor-α (TNF-α) (Gibco, Thermo
Fisher Scientific, CA, USA) 2 ng/mL each or lipopolysaccharide (LPS, from Escherichia coli
055:B5, Sigma-Aldrich, St. Louis, USA) 1 μg/mL in the presence or absence of genistein for 24
hours [21]. The control cells were left untreated.
Indirect psoriatic stimulation. The Transwell cell culture system was used to co-culture
THP-1 with HaCaT. THP-1 cells (3 x 106) were cultured in the upper compartment in cell cul-
ture membrane inserts (Corning #353102), and HaCaT cells (4 x 105) were cultured in the
lower compartment in 6-well plates, both cell lines in RPMI medium supplemented with 10%
FBS and 1% antibiotic/antimycotic solution. For the co-cultivation studies, HaCaT cells grown
in six-well plates were washed twice with phosphate buffered saline (PBS). The cell culture
insert was then placed on top of the HaCaT cells to avoid physical contact of the different cell
lines (indirect co-culture). HaCaT and THP-1 cells were stimulated with 1 μg/mL LPS (Sigma-
Aldrich, St. Louis, USA) for 24 hours of co-culturing with the Transwell cell culture inserts.
Additionally, 3 mL supplemented RPMI medium was added to the HaCaT monolayer
(control).
DNA microarray processing and real-time quantitative RT-PCR assays for
mRNA analysis
Total RNA was extracted from cells using the High Pure RNA Isolation Kit (Roche Applied
Science, Indianapolis, USA) following the manufacturer’s instructions. The quality and quan-
tity of each RNA sample was evaluated using the RNA 6000 Nano Assay on the Agilent 2100
Bioanalyser (Agilent Technologies Inc., USA). Next, total RNA was retrotranscribed with the
Transcriptor First-Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, USA).
To identify genes regulated differentially by genistein, we compared the expression levels of ca.
25,000 genes from genistein- and vehicle-treated keratinocytes. Gene expression data have
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been deposited in the NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo, GEO Series accession number GSE60971), according to the Minimum Information
About a Microarray Experiment (MIAME) standards. Three biological replicates (n) were con-
ducted for the microarray analysis with the use of Illumina’s Human HT-12 v4 Expression
BeadChips (Illumina Inc.). The Illumina TotalPrep RNA amplification kit (Ambion) was uti-
lized in order to amplify total input RNA. BeadChips were scanned using the Illumina BeadAr-
ray Reader and Bead Scan software (Illumina Inc.). To identify the genes that are differentially
expressed between studied groups, we have applied an arbitrary threshold in the form of fold
change (FC) > 1.3, and below 0.7, with the p-value 0.05 based on t-test comparisons. In addi-
tion, our criteria for selection of the DEGs were dictated by other considerations. A small fold
change, if it co-occurred with the respective factor, would have a much larger impact than a
larger fold change when the factor was not expressed. This to say that we prefer to be less strin-
gent in detecting the DEGs, but then we put more care in extracting the important and coher-
ent biological signals from the output (e.g., through gene set enrichment analysis [GSEA]).
In addition, we performed statistical testing for multiple comparisons by the false discovery
rate (FDR) correction calculation (Benjamini-Hochberg’s test). In this, all differential expres-
sion p-values were FDR adjusted using the q-value Bioconductor package [22].
Real-time quantitative reverse transcription polymerase chain reaction (real-time qRT-PCR)
was carried out with the Human Reference Gene Panel (Roche Applied Science, Indianapolis,
USA), Real-Time ready Custom Panels (panel 1: config. no. 100072633; and panel 2: config. no.
100078604, Roche Applied Science, Indianapolis, USA) and the LightCycler1 480 Probes Master
(Roche Applied Science, Indianapolis, USA) using the Light Cycler 480 II detection system
(Roche). Expression values were normalized against three control genes RPLP0, TBP, and YWHAZ
of constant expression level. The primers used for real-time qRT-PCR assessment of psoriatic
HaCaT cell line stimulation were: LOR (Left: GCTCTGTCTGCGGCTACTCT;Right: AGTGACCTG
CTGCGAGGA),KRT10 (Left: TAGCAGCTTTGGTGGGAGTT; Right: CTGCCACCTCCGAAACTG),
S100A7 (Left: AAGCCTGCTGACGATGATG; Right: CGAGGTAATTTGTGCCCTTT), S100A9 (Left:
AGAAGATGCACGAGGGTGAC; Right: TGGCCACTGTGGTCTTAGG)and Universal ProbeLibrary
Human TBPGene Assay (Roche Applied Science, Indianapolis, USA).
Gene Ontology and gene set enrichment studies
Gene Ontology analysis and data visualization were performed using the web tools GOrilla
(http://cbl-gorilla.cs.technion.ac.il/) and lists of genes with up- and down-regulated expression
separately, restricting the output to biological process and cell compartment.
GSEA was performed as previously described [23, 24] to illustrate Kyoto Encyclopedia
of Genes and Genomes (KEGG)_Pathways, Biological Processes and Molecular Function
enriched among genistein treated HaCaT gene sets. A nominal p-value< 0.01 and a FDR
0.25 were used to assess the significance of the enrichment scores. GSEA ranked list of KEGG
defined pathways was created with the normalized enrichment score (NES) as the leading
parameter. NES is the primary statistic for examining gene set enrichment results and can be
used to compare analysis results across gene sets. Additionally, a particular pathway was con-
sidered significantly enriched if its NES had a q-value of an FDR-correction below or equal
25%. An FDR of 25% indicates that the result is likely to be valid 3 out of 4 times. The use of a
more stringent FDR cutoff may lead to overlooking potentially significant results.
PI3K phosphorylation analysis
In this part of the work we studied the activity of phosphatidylinositol-3-kinase (PI3K)
in HaCaT cells treated with 0.05% DMSO only, stimulated with a combination of
Isoflavone genistein in the epithelial cell line HaCaT
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proinflammatory “cytokine mix” and treated with 100 μM genistein or stimulated with a com-
bination of proinflammatory “cytokine mix” and treated with wortmannin (a PI3K inhibitor).
Percentage of inactivated cells, activated cells (via PI3K phosphorylation), and non-expressing
cells was determined for each experimental condition. HaCaT cells were seeded at a density of
4 x 105 cells/well into 6-well plates in defined Keratinocyte-SFM medium (Gibco, Thermo
Fisher Scientific, CA, USA) supplemented with a pituitary extract including BPE and EGF
(Gibco, Thermo Fisher Scientific, CA, USA). After 24 hours, the culture medium was replaced
with serum-free keratinocyte medium without growth supplements for a 16-hour incubation.
For further experiments cells were pretreated with 100 μM genistein for 2 hours, and then
incubated with a combination of proinflammatory “cytokine mix” (Gibco, Thermo Fisher Sci-
entific CA, USA; Sigma-Aldrich, St. Louis, USA) for 30 minutes. The control cells were left
untreated. The suspended cells were collected, and the phosphorylation of PI3K was deter-
mined by MUSE1 Cell Analyzer (Merck Millipore, Germany) using a commercial kit
Muse1 PI3K Activation Dual Detection Kit (Merck Millipore, Germany) according to the
manufacturer’s instructions. An average of 10,000 cells were analyzed for each condition. Trip-
licate independent experiments were conducted.
NF-κB activation assessment
For immunostaining, rabbit monoclonal antibody NF-κB p65 (D14E12) XP1 Rabbit mAb
(Cell Signaling Technology, Danvers, USA) was used (1:400, incubated overnight in 4˚C) with
a secondary antibody, anti-rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor1 488 Conjugate,
Cell Signaling Technology, Danvers, USA) used at 1:250 (incubated 2 hours at room tempera-
ture in the dark). Rabbit serum (10%) (Sigma-Aldrich, St. Louis, USA), used as a blocking
buffer, eliminated all non-specific binding of the secondary antibody. Nuclei were counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI) (Slow Fade Diamond Antifade Mountant
with DAPI, Molecular Probes, Eugene, OR, USA) for 1 hour in the dark. Images were taken
using a fluorescent microscope (Leica) with x40 magnification. Cells were plated in chamber
slides (Millicell EZ SLIDES, Merck Millipore, Billerica, MA, USA) in supplemented defined
Keratinocyte-SFM medium (Gibco, Thermo Fisher Scientific, CA, USA). After a 24-hour incu-
bation, cells were cultivated in serum-free keratinocyte medium without growth supplements
for 16 hours. For further experiments, the cells were pretreated with 100 μM genistein for 2
hours, and then incubated with a combination of proinflammatory “cytokine mix” (Gibco,
Thermo Fisher Scientific, CA, USA; Sigma-Aldrich, St. Louis, USA) for 30 minutes. The con-
trol cells were left untreated.
Detection of reactive oxygen species (ROS) by fluorescent microscopy
To elucidate the mechanism of genistein-induced inhibition of the NF-κB nuclear transloca-
tion, we performed experiments to determine the effects of the tested isoflavone compound on
intracellular reactive oxygen species (ROS) accumulation. The intracellular accumulation of
ROS was monitored using CellROX1 Deep Red Reagent (Molecular Probes, Thermo Fisher
Scientific, CA, USA). HaCaT cells were seeded in chamber slides (Millicell EZ SLIDES, Merck
Millipore, Billerica, MA, USA) in supplemented defined Keratinocyte-SFM medium (Gibco,
Thermo Fisher Scientific, CA, USA). After a 24-hour incubation cells were further cultivated
in serum-free keratinocyte medium without growth supplements for 16 hours. For experimen-
tal procedure cells were pretreated with 100 μM genistein or 10 mM N-acetyl-l-cysteine
(NAC) for 2 hours, and then incubated with a combination of proinflammatory “cytokine
mix” or TNF-α 10 ng/mL or LPS 1μg/mL (Gibco, Thermo Fisher Scientific, CA, USA; Sigma-
Aldrich, St. Louis, USA) for 30 minutes. The control cells were left untreated. At the end of the
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treatment, cells were loaded with the CellROX1 Reagent at a final concentration of 5 μM and
incubated for 30 minutes at 37˚C. Cells were then washed three times with PBS. Nuclei were
counterstained with DAPI (Slow Fade Diamond Antifade Mountant with DAPI, Molecular
Probes, Eugene, OR, USA) for 1 hour in the dark. Samples were observed under a fluorescence
microscope (Leica) with x40 magnification.
Analysis of ROS by fluorescent cell analyzer
Quantitative measurements of ROS was acquired with Muse1 Oxidative Stress Kit (Merck
Millipore, Germany). HaCaT cells were seeded at a density of 4 x 105 cells/well into 6-well
plates in defined Keratinocyte-SFM medium (Gibco, Thermo Fisher Scientific, CA, USA) sup-
plemented with a pituitary extract including BPE and EGF (Gibco, Thermo Fisher Scientific,
CA, USA). After a 24-hour incubation, cells were cultivated in serum-free keratinocyte
medium without growth supplements for 16 hours. For experimental analysis cells were pre-
treated with 100 μM genistein or 10 mM NAC for 2 hours, and then incubated with a combi-
nation of proinflammatory “cytokine mix” or TNF-α 10 ng/mL or LPS 1μg/mL (Gibco,
Thermo Fisher Scientific, CA, USA; Sigma-Aldrich, St. Louis, USA) for 30 minutes. The con-
trol cells were left untreated. Trypsinized cells were collected, and the count and percentage of
cells undergoing oxidative stress based on the intracellular detection of superoxide radicals
were determined by MUSE1 Cell Analyzer (Merck, Millipore, Germany) using a commercial
kit Muse1 Oxidative Stress Kit (Merck Millipore, Germany) according to the manufacturer’s
instructions. An average of 10,000 cells were analyzed for each condition. Triplicate indepen-
dent experiments were conducted.
ELISA for cytokines
The cells were seeded at the 4 x 105 cells per well in 6-well-plates in defined Keratinocyte-SFM
medium (Gibco, Thermo Fisher Scientific, CA, USA) supplemented with a pituitary extract
including BPE and EGF (Gibco, Thermo Fisher Scientific, CA, USA). After a 24-hour incuba-
tion cells were cultivated in serum-free keratinocyte medium without growth supplements for
16 hours. Then, the cells were, respectively, pretreated with 100 μM genistein or 1 μM MTX
for 2 hours and stimulated with a combination of proinflammatory “cytokine mix” or TNF-α
10 ng/mL or LPS 1μg/mL (Gibco, Thermo Fisher Scientific, CA, USA; Sigma-Aldrich,
St. Louis, USA) for 24 h. The control cells were left untreated. The IL-1B, IL-8, IL-20, CCL2,
and TGF-β1 levels in the cell culture supernatants were measured by enzyme-linked immuno-
sorbent assay (ELISA) using kits purchased from EIAab Science (Wuhan, China). The optical
density of each well was determined using a microplate reader (VICTOR Multilabel Plate
Reader, PerkinElmer).
Results
Identification of genistein-responsive genes
No remarkable cytotoxicity features of genistein were observed in the range of tested condi-
tions, while inhibition of proliferation of keratinocytes in a dose-dependent manner was
detected (S1 Fig and raw data in S1 Table, S2 Table). Although a decline in proliferation by
50% was observed for keratinocytes incubated in the presence of about 20 μM genistein for
more than 7 days, we decided to set the concentration of genistein at 100 μM for the following
experiments, as rather short in time expositions of cells (i.e., maximally 48 hours) to the com-
pound were carried out.
Isoflavone genistein in the epithelial cell line HaCaT
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To identify genes regulated differentially by genistein, we compared the expression levels of
ca. 25,000 genes from genistein- and vehicle-treated keratinocytes. Gene expression data have
been deposited in the NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo, GEO Series accession number GSE60971), according to the Minimum Information
About a Microarray Experiment (MIAME) standards. Testing the effects of genistein on
human HaCaT transcriptome via the microarray analysis, we found that this compound
induced significant dose- and time-dependent alterations in profiles of hundreds of transcripts
(Fig 1A). As discovered in three independent assays, in total 4039 transcripts for 24 hours and
4186 for 48 hours handling with 100 μM genistein were affected. These changes included
many psoriasis-related genes, which design a so-called psoriasis gene-expression profile (Fig
1B). In total, 214 psoriasis related-genes with differential expression (PRGwDE) were selected
on the basis of the classification criteria referring to the most up-to-date scientific reports
describing a list of genes with significantly differentiated activity obtained in both in vitro and
in vivo analyses when studying psoriatic phenotypes, at least a couple of times stated in unre-
lated literature sources [1, 2, 4–6, 25–28]. Except for published psoriasis-related DEG lists, we
also studied and reviewed the psoriasis associated genes database (PAGD), as well as the data-
base of genes associated with psoriasis (dbGAP). Among those 214 PRGwDE, 39 genes (i.e.
AKR1C3,ALDH3A2,AMD1, C1QBP, CCL2,CCNF,CD47,CDC25A,CEBPD, EIF5, EIF5A,
FOXO1, GJB2, HPSE, HSPA8, HSPE1, HSPH1, ID1, IL-1A, IL-1B, IL-20RB, IL-8, IRAK1,
KPNB1, LAD1, LDLR, MALL, MAPKAPK3, PGAM1, PGD, PI3, POR, RNF141, S100A9,
SPRR1B, SRM, TCN1,TCP1 and TIMP3) belong to a common set of 2622 genes with modu-
lated expression in cells exposed to 100 μM genistein for 24 and 48 hours. These genes are
potential therapeutic targets due to the normalization of their dysfunctional activity in psori-
atic cells after exposure to genistein (including some key transcripts) and may be important
for the condition. The application of Fisher’s exact test gave a one-tailed probability of
p = 0.002523, which is significant beyond the 5% level. In total, 39 out of 214 genes belonging
to the 2611 DEGs modulated by genistein are a significant quantity when referred to ca. 25,000
cellular genes. Interestingly, taking into consideration our previous results on the use of genis-
tein-treated HDFa fibroblasts [29] we found that 19 (i.e., AKR1C3,ALDH3A2, AURKA, CCNF,
CD47,CEBPD, EIF5, FOXO1, HMOX1, HSPE1, IL8, KPNA2, KPNB1, LDLR, MALL, PGD,
POR, RNF141, and TIMP3) of the 39 genes deregulated upon treatment with genistein and
PRGwDE were common for keratinocytes and fibroblasts, both treated with 100 μM genistein
for 24 hours (S2 Fig).
Furthermore, by selecting informative genes from microarray data via Gene Ontology
(GO) analysis, we recognized that tested conditions altered the expression of genes belonging
to a wide range of pathways involved in “Biological processes’” and “Cellular Compartment”
organization (Fig 1C). The functional annotation analyses of the genes with up-regulated
expression upon treatment with genistein of HaCaT highlighted GO groups associated with
lipid metabolic pathways, autophagy regulation processes and oxidation-reduction processes,
while for the transcripts at the reduced level, a number of processes involved in ncRNA,
rRNA, nucleic acid and cell cycle procedures were revealed (Fig 1C–1). Further, GO “Cellular
Compartment” categories related to intracellular, cytoplasmic and membrane-bounded organ-
elles were highlighted for the analysis of the up-regulated genes from the comparison between
genistein-treated and control keratinocytes. In turn, the examination of genes with down-reg-
ulated expression upon treatment with genistein of HaCaT showed modulation of transcripts
related to nuclear and intracellular organelle parts, pre-ribosome and mitochondrial compart-
ments (Fig 1C–2). Accordingly, bench of KEGG_Pathways enriched among genes up- and
down-regulated by 100 μM genistein treatment for 24 and 48 hours in HaCaT cells based on
GSEA analysis is presented in Fig 2, sections A–D, with a significant enrichment of gene sets
Isoflavone genistein in the epithelial cell line HaCaT
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Fig 1. Identification of genistein-responsive genes. (A) Graphs illustrating distribution of up- (in red) and down-regulated (in blue) genes of whole HaCaT genomes
after 24 and 48 hours treatment with 30, 60, and 100 μM genistein. The digits are numbers of transcripts identified as changed under studied conditions. DMSO-treated
cells were used in control experiments. Significantly differentially expressed genes had a fold change of> 1.3, and below 0.7, with the p-value< 0.05 and n = 3. (B) Venn
diagrams illustrating distribution of deregulated genes of whole HaCaT genomes after 24 hours (HaCaT_24 h) and 48 hours (HaCaT_48 h) of treatment with 100 μM
genistein or PRGwDE compared to the respective untreated conditions. (C) GO analysis by “Biological Processes” (C-1) and “Cellular Compartment” (C-2) category of
the genes with up- and down-regulated expression upon 100 μM treatment with genistein for 24 hours (black columns) and 48 hours (yellow columns) of HaCaT, with
FDR 0.25, fold change> 1.3 and< 0.7, p< 0.01 and n = 3.
https://doi.org/10.1371/journal.pone.0192297.g001
Isoflavone genistein in the epithelial cell line HaCaT
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(marked in bold italics) with important roles in pathogenetic mechanisms responsible for the
induction of psoriasis or in any other ways related to this dermatosis. In general, interpretation
of the biological meaning of defining gene sets described in detail in the table in Fig 2 revealed
the top 30 canonical pathways from 56 and 53 up- and down-regulated, respectively, after 24
hours and from 53 and 26 up- and down-regulated, respectively, after 48 hours treatment with
genistein enriched among the leading edge gene subsets, with p-value< 0.01 and FDR 0.25.
Within the list of up-regulated gene sets, various metabolic pathways, the peroxisome and per-
oxisome proliferator-activated receptor (PPAR) signaling pathway (important in psoriasis and
keratinocyte homeostasis), p53 signaling pathway, and some more were found. Among the
down-regulated gene sets, we detected genes belonging to a wide range of pathways involved
in nucleotide-binding oligomerization domain-like (NOD-like) receptor signaling, pathogenic
Escherichia coli infection, purine and pyrimidine metabolism, extracellular matrix (ECM)
receptor interaction associated with the mutual communications between the leukocytes-
extracellular matrix, mitogen-activated protein kinase (MAPK) and mechanistic target of rapa-
mycin (MTOR) signaling pathways, and apoptosis. Fig 2, section E shows graphs presenting
Fig 2. Bench of KEGG_Pathways enriched among genes up- (A, C) and down-regulated (B, D) by genistein 24 hours (A, B) and 48 hours (D, E) treatment in HaCaT
based on GSEA, (Size, number of genes in each set; NES, normalized enrichment score; FDR q-val, q-value of false discovery rate), with gene sets of significant role in
pathogenetic mechanisms responsible for the induction of psoriasis. The top 30 canonical pathways from 56 and 53 up- and down-regulated, respectively, after 24 hours and
from 53 and 26 up- and down-regulated, respectively, after 48 hours treatment with genistein, enriched among the leading edge gene subsets, p-value< 0.01 and FDR 0.25
are illustrated. KEGG_Pathways with roles in psoriasis development are marked in bold italics. (E) GSEA analysis of mostly enriched KEGG_Pathways with roles in psoriasis
development. The enrichment score is shown as a scattered black line, and the horizontal black bars next to the plot indicate the position of pathway-associated genes.
Fraction of genes with essentially modulated expression is shown as GSEA-derived heat map.
https://doi.org/10.1371/journal.pone.0192297.g002
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genes and the enrichment plots generated by GSEA analysis of mostly enriched KEGG Path-
ways with role in psoriasis development (i.e., KEGG_Glutathione metabolism, KEGG_NOD-
like receptor signaling pathway, KEGG_Arginine and proline metabolism, and KEGG_Patho-
genic Escherichia coli infection). In addition, results of annotation enrichment analysis of
“Biological Processes”, “Molecular Function”, and “Cellular Compartment” terms identified in
the GSEA revealed that the treatment of keratinocytes with 100 μM genistein for 24 and 48
hours significantly altered the expression of a wide range of transcripts, including psoriasis-
related genes involved in numerous processes activated/deactivated in psoriasis (S3 Fig).
To provide independent validation of our microarray data and to examine in more detail
the expression patterns of psoriasis-related genes involved, we used a real-time qRT-PCR
approach. At this point, determination of potential candidates for endogenous control as refer-
ence genes for real-time qRT-PCR was assessed using commercially available RealTime ready
Human Reference Gene Panel. Moreover, statistical analyses of the normalized gene expres-
sion data were performed in Prism (BestKeeper) (S3 Table). Among all genes, three (RPLPO,
TBP, and YWHAZ–the first two in case of panel 1 usage, and the latter two in case of panel 2
application), were selected as references. Following confirmation of microarray results by real-
time qRT-PCR, 30 from 45 tested psoriasis-associated genes belonging to real-time qRT-PCR
custom panel 1 is provided in Table 1. Modulation of their activities after genistein treatment,
by reducing the expression efficacy of 19 transcripts with enhanced levels in HaCaT cells and
by stimulating the expression efficiency of 11 mRNAs revealing decreased activity in keratino-
cytes, was documented.
As already mentioned above, although genistein exerts potent anti-inflammatory effects,
DNA microarray analysis on HaCaT cells hardly revealed modulation in activity of genes of
inflammation-immune axis regulation. This in turn could be due to the applied cell culture
model of normal, not mimicking or non-psoriatic keratinocytes. A 2D cell culture model of
human skin that closely mimics the pathways leading to psoriatic skin formation was therefore
developed and evaluated at the next phase of our work (S4 Table). Among the three different
approaches tested in our study to induce a “psoriasis-like” inflammatory response in keratino-
cytes, we selected a method with direct treatment of the HaCaT cells with a mix of proinflam-
matory cytokines (IL-1A, IL-17A, IL-22), oncostatin M (OSM) and tumor necrosis factor-α
(TNF-α) as the most efficient in terms of the expected characteristics. The evaluation results
indicated that this assay model is able to process and provide an in vitro system capable of test-
ing for a compounds ability to inhibit psoriasis-driving mechanisms (S4 Table). Thus, tran-
scriptomic profiling with the use in this case of two real-time qRT-PCR custom panels, 1 and 2
(Real-Time ready Custom Panels for screening of in sum 90 psoriasis-related transcripts), on
“psoriasis-like’” HaCaT cells, treated and untreated with genistein, was performed and deter-
mined relative to those on genistein-untreated non-psoriatic (i.e., not stimulated with a combi-
nation of proinflammatory “cytokine mix”) keratinocytes (Fig 3A–3D). The analysis revealed
significant alteration in the activity of 25 of 45 genes tested with the use of panel 1, and 38 of
45 genes tested with the use of panel 2. Measurements determined by the two transcript assess-
ment systems, panel 1 and panel 2, using endogenous references RPLPO (Fig 3A) and TBP
(Fig 3B) in the case of panel 1 and using endogenous references YWHAZ (Fig 3C) and TBP
(Fig 3D) in the case of panel 2, showed various clusters of gene activity. Except for a set of
genes with unchanged expression for both panels (i.e., 20 transcripts of panel 1 representative
of psoriasis-related genes and 7 transcripts of panel 2 representative of inflammation-immune
axis regulation genes), we observed the occurrence of four main profiles of gene responses
composing particular clusters, common for both panels 1 and 2. The first and second cluster,
respectively, cover genes of their reduced activity or of their increased expression in response
to both “cytokine mix” stimulation and proinflammatory “cytokine mix” stimulation plus
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genistein treatment. The third group includes genes of decreased expression after “cytokine
mix” stimulation, while enhanced activity as a result of exposure to the “cytokine mix” plus
genistein. The fourth cluster genes of increased activity after “cytokine mix” activation and its
reduction after incubation with the “cytokine mix” plus genistein, as is depicted in the internal
drawings in Fig 3. Additionally, in the case of panel 2 with inflammation-immune axis
Table 1. Expression patterns of 30 psoriasis-associated genes analyzed with the use of DNA microarray and real-time qRT-PCR custom panel 1.
Microarray Real-time qRT-PCR
FC ± SD
Gene Gene product 24 h 48 h 24 h
vs. RPLPO
24 h
vs. TBP
▲ up-regulated
ACACB Acetyl-CoA Carboxylase Beta 3.4 ± 0.4 3.9 ± 0.2 3.8 ± 0.7 3.9 ± 0.5
CAT Catalase 1.8 ± 0.2 1.7 ± 0.1 2.3 ± 0.4 2.8 ± 0.2
FADS1 Fatty Acid Desaturase 1 3.7 ± 0.2 3.6 ± 0.2 3.3 ± 0.3 4.0 ± 0.2
FASN Fatty Acid Synthase 2.1 ± 0.0 2.6 ± 0.4 6.8 ± 1.3 5.7 ± 1.0
FOXC1 Forkhead Box C1 1.6 ± 0.2 1.9 ± 0.2 1.8 ± 0.3 2.0 ± 0.2
FOXO1 Forkhead Box O1 1.8 ± 0.1 2.2 ± 0.2 1.7 ± 0.1 2.1 ± 0.2
JUN AP-1 Transcription Factor Subunit 1.1 ± 0.1 3.2 ± 0.1 2.9 ± 0.9 2.9 ± 0.5
MEGF9 Multiple EGF Like Domains 9 1.7 ± 0.3 1.5 ± 0.1 2.3 ± 0.4 2.7 ± 0.2
MYH10 Myosin Heavy Chain 10 1.5 ± 0.1 1.8 ± 0.0 1.5 ± 0.2 1.5 ± 0.0
PCYOX1 Prenylcysteine Oxidase 1 1.8 ± 0.1 1.7 ± 0.1 1.6 ± 0.2 1.7 ± 0.1
RHOB Ras Homolog Family Member B 2.0 ± 0.3 2.9 ± 0.3 3.7 ± 0.8 4.2 ± 0.1
RHOBTB3 Rho Related BTB Domain Containing 3 2.0 ± 0.0 1.8 ± 0.1 2.3 ± 0.2 2.7 ± 0.1
SSPN Sarcospan 2.7 ± 0.3 2.0 ± 0.2 5.8 ± 0.5 8.5 ± 0.8
TIMP3 Tissue Inhibitors of Metalloproteinases 3 1.5 ± 0.3 2.0 ± 0.3 2.2 ± 0.2 2.3 ± 0.4
TUFT1 Tuftelin 1 1.5 ± 0.1 1.9 ± 0.0 2.4 ± 0.3 2.6 ± 0.2
UST Uronyl 2-sulfotransferase 2.3 ± 0.2 2.8 ± 0.1 2.1 ± 0.3 2.5 ± 0.1
ZNF12 Zinc Finger Protein 12 1.2 ± 0.1 1.7 ± 0.1 1.5 ± 0.2 1.5 ± 0.1
ZNF483 Zinc Finger Protein 483 2.1 ± 0.3 1.8 ± 0.4 3.2 ± 0.0 2.4 ± 0.0
ZNF652 Zinc Finger Protein 652 2.0 ± 0.0 1.6 ± 0.4 1.6 ± 0.0 1.8 ± 0.2
▼ down-regulated
CDC25A Cell Division Control Protein 42 Effector Protein 5 0.4 ± 0.0 0.3 ± 0.0 0.8 ± 0.2 0.7 ± 0.2
EZH2 Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.1 0.9 ±0.0
F12 Coagulation Factor XII 0.4 ± 0.1 0.4 ± 0.0 0.2 ± 0.1 0.2 ± 0.0
GJB2 Gap Junction Protein Beta 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
KRT6B Keratin 6B 0.4 ± 0.0 0.5 ± 0.0 0.4 ± 0.1 0.5 ± 0.0
MALL T-cell Differentiation Protein Like 0.3 ± 0.0 0.5 ± 0.0 0.4 ± 0.1 0.5 ± 0.0
PI3 Peptidase Inhibitor 3 0.2 ± 0.0 0.1 ± 0.1 0.2 ± 0.1 0.3 ± 0.1
SERPINB8 Serpin Family B Member 8 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
SRM Spermidine Synthase 0.5 ± 0.1 0.4 ± 0.0 0.3 ± 0.1 0.3 ± 0.0
SYNCRIP Synaptotagmin Binding Cytoplasmic RNA Interacting Protein 0.3 ± 0.0 0.4 ± 0.0 0.6 ± 0.1 0.6 ± 0.1
THBD Thrombomodulin 0.4 ± 0.1 0.4 ± 0.1 0.9 ± 0.2 0.9 ± 0.1
Alterations in mRNA levels of selected genes in HaCaT after 24 and 48 hours (DNA microarray) and 24 hours (real-time qRT-PCR custom panel 1) of 100 μM genistein
treatment referred to 0.7 > FC > 1.3 with a p-value< 0.05. The microarray and real-time qRT-PCR data represent averaged values ± standard deviation (SD) from
n 3, and denote significant differences for samples treated with genistein against non-treated samples, with respect to the reference genes RPLPO and TBP of constant
expression level implemented for real-time qRT-PCR analysis. At this point determination of potential candidates for endogenous control as reference genes for real-
time qRT-PCR was assessed using the commercially available RealTime ready Human Reference Gene Panel. Moreover, statistical analyses of the normalized gene
expression data were performed in Prism (BestKeeper) (see S3 Table).
https://doi.org/10.1371/journal.pone.0192297.t001
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regulation genes, we detected the existence of an additional cluster, the fifth one, with genes of
their reduced activity in response to “cytokine mix” stimulation, followed by maintenance at
the same level of activity after incubation with the “cytokine mix” plus genistein (Fig 3C and
3D).
No effect of genistein on PI3K activity in keratinocytes with induced NF-κB
signaling
In this part of the work we studied the activity of PI3K in HaCaT cells treated with 0.05%
DMSO only, stimulated with a combination of proinflammatory “cytokine mix”, stimulated
with a combination of proinflammatory “cytokine mix” and treated with 100 μM genistein, or
stimulated with a combination of proinflammatory ‘cytokine mix’ and treated with wortman-
nin (a PI3K inhibitor). Percentage of inactivated cells, activated cells (via PI3K phosphoryla-
tion), and non-expressing cells was determined for each experimental condition. The results
obtained from three independent experiments revealed no significant differences in PI3K
activity between cells activated with “cytokine mix” and non-activated cells (S5 Table). Addi-
tionally, keratinocytes stimulated with “cytokine mix” and treated with genistein exhibited
PI3K activity at the level of non-activated cells. Statistical analysis performed by using one-way
ANOVA and Tukey’s honest significant difference (HSD) showed no significant differences in
cell viability relative to control cells (treated with 0.05% DMSO only). Despite this data, we
found a two-fold increase in PI3K gene activity after stimulation with “cytokine mix”, followed
by an app. 1.5-fold decrease after exposure of these cells to genistein (S5 Table).
Next, we studied the effect of genistein on nuclear translocation of the NF-κB p65 subunit.
To accomplish this, we performed laser scanning indirect immunofluorescence confocal
microscopy using an antibody to the p65 molecule. As shown in Fig 4, the immunofluores-
cence staining pattern showed clearly the translocation of p65 into the nucleus of human kera-
tinocytes after activation with a cytokine cocktail. Similarly and as expected, the p65 molecule
remained in the cytoplasm of stimulated keratinocytes with a combination of proinflammatory
“cytokine mix” and treated with genistein. Additionally, to assess activation of the NF-κB p65
subunit following TNF-α stimulation plus genistein exposure, we examined p65 molecule
nuclear translocation in keratinocytes treated with these compounds. Our results pointed to
the effect of genistein on NF-κB p65 nuclear translocation when cells were activated with
TNF-α alone instead of a cytokine cocktail, as the p65 molecule remained in the cytoplasm of
cells (S4 Fig). Based on these results, we conclude that genistein suppresses either “cytokine
mix” or TNF-α-induced nuclear factor κB p65 subunit translocation into nucleus.
Attenuation of the level of reactive oxygen species (ROS) by genistein
To elucidate the mechanism of genistein-induced inhibition of NF-κB nuclear translocation,
we performed experiments to determine the effects of the tested isoflavone compound on
intracellular ROS accumulation. At first, attenuation of ROS levels by genistein was examined
by confocal fluorescence microscopy (Fig 5A). In addition, significant differences (p 0.05)
between cell populations not expressing intracellular ROS (ROS [–] cells) and expressing
Fig 3. Transcriptomic profiling with the use in this case of two real-time qRT-PCR custom panels, 1 and 2, on “psoriasis-like” HaCaT cells,
treated with and without genistein. Normalized to unstimulated HaCaT cells, relative real-time qRT-PCR values denoting differences for
keratinocyte samples incubated with a proinflammatory “cytokine mix” (yellow bars), and keratinocyte samples incubated with a proinflammatory
“cytokine mix” and treated with 100 μM genistein (green bars), with respect to the reference genes of constant expression (i.e., RPLPO (A) and TBP
(B) in the case of panel 1, and YWHAZ (C) and TBP (D) in the case of panel 2). Alterations in mRNA levels of genes are referred to 0.7> FC> 1.3
with the p-value< 0.05. The data represent averaged values ± standard deviation from n 3. The occurrence of four (A, B) or five (C, D) various
profiles of gene responses is imaged for each group in the form of graphical inserts located at the bottom of the charts.
https://doi.org/10.1371/journal.pone.0192297.g003
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intracellular ROS (ROS [+] cells) were observed with the use of a fluorescent cell analyzer for
all tested conditions except for LPS, where cell numbers of ROS (-) and ROS (+) cells were
comparable (Fig 5B and raw data in S6 Table). Furthermore, stimulation of HaCaT keratino-
cytes with a combination of proinflammatory “cytokine mix” corresponding to a concentra-
tion of 2 ng/mL (ACT 2) or 5 ng/mL (ACT 5) in each compound of the mix did not increase
intracellular ROS levels. Increased expression of intracellular ROS was observed only when
TNF-α or LPS activation of HaCaT cells was applied, which in turn was effectively attenuated
by treatment with genistein or NAC (a common scavenger of ROS) (Fig 5B and raw data in S6
Table).
Reduction of proinflammatory cytokine production following genistein
treatment
It has been well documented that overproduction of inflammatory cytokines is implicated in
the pathogenesis of psoriasis. Therefore, we explored whether genistein (100 μM) could sup-
press expression levels of selected inflammatory proteins in keratinocytes stimulated with a
combination of “cytokine mix” at a concentration of 2 ng/mL for each constituent compound
Fig 4. Effect of genistein on NF-κB p65 subunit induction. Keratinocytes were pretreated with or without 100 μM
genistein (GEN) for 2 hours, and then incubated with a proinflammatory “cytokine mix” (ACT). DMSO-treated,
unstimulated cells were used as the control (NACT). Nuclear translocation of the NF-κB p65 subunit was assessed by
indirect immunofluorescence confocal microscopy using anti-p65 subunit antibodies and appropriate fluorescently
tagged secondary antibodies. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). Results representative
of three independent experiments (with scale bars 25 μm) are shown.
https://doi.org/10.1371/journal.pone.0192297.g004
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or 10 ng/mL TNF-α or 1μg/mL LPS alone. In addition, 1 μM MTX (a drug well known drug
diminishing cytokine production and their cellular amounts) was included in our tests [30–
32]. In the course of our studies, we first found that the expression of IL-8, IL-20, and CCL2
(but not IL-1B and TGF-β1) was significantly elevated in keratinocytes regardless of the cell
activation method used, except for IL-20 where neither TNF-α nor LPS stimulation influenced
alterations of the level of this cytokine. Next, we showed that genistein considerably inhibits
levels of IL-8, IL-20, and CCL2, but not IL-1B and TGF-β1 (Fig 6 and raw data in S7 Table).
The effect of genistein was basically close to the outcome that we observed for MTX. Surpris-
ingly, MTX, which is the drug of choice for conventional psoriasis treatment, exhibited rather
weak inhibitory effects on the tested inflammatory cytokines in HaCaT cells, with the biggest
impact (as much as three times more potent than genistein) only on IL-8 when cells were
treated with TNF-α. On the other hand, it is also known that the results of this type of analysis
may vary depending on the research model used, which in our case was HaCaT cell line (not
in vivo material, such as serum or synovial fluid), where the effect of MTX on cytokines was
conspicuous.
Discussion
First, Ps therapies included arsenic and ammoniated mercury use in the 19th Century [33, 34].
In the 1950s corticosteroids were developed as a new topical treatment [33] and were followed
in the 1970s by use of MTX and psoralen ultra-violet A (PUVA) [35]. In the 1980s, Ps treat-
ment with narrowband ultraviolet B (UVB) [36], retinoids [37], and vitamin D therapies were
added [38]. From the 1990s to the present, manipulating the immune system to treat psoriasis
has been explored first with cyclosporine [39] and more recently with targeted molecules–bio-
logical drugs [40]. Biologic therapies make use of specific molecules that target particular pro-
teins implicated in immune-mediated disease. In dermatology, the approved and emerging
biologic therapies work extracellularly to alter T-cell activation and differentiation, block cyto-
kines, or eliminate pathogenic B-cells [41]. The current treatment options for psoriasis and
psoriatic arthritis include TNF-α blockers and IL-12, IL-17, IL-23, T-cell and B-cell inhibitors
[42]. After decades of research, there are many treatments available to help manage the symp-
toms of Ps, however, as yet, there is no sufficient cure. One of possible reasons might be a
multi-syndromic form of the disease, which raises obstacles for one drug to focus on so many
“hot spots”. Another important aspect is comorbidities, not always taken into account and
hard to manage with single drug therapy. Because the disease is chronic, and essentially incur-
able, both acutely acting agents and those effective as long-term maintenance are needed. Nat-
ural compounds with anti-inflammatory activities are applied all over the world as alternative
medicines for psoriasis because of their perceived beneficial impact on the skin. Among them
are isoflavones, the most abundant phytoestrogens in soybeans (Glycine max (L.) Merr.),
structurally similar to 17 beta-estradiol [43]. Soybeans and its major active compound
Fig 5. Attenuation of the level of reactive oxygen species (ROS) by genistein. (A) Keratinocytes were stimulated respectively with a proinflammatory “cytokine mix”
corresponding to a concentration of 2 ng/mL (ACT 2) or 5 ng/mL (ACT 5) in each compound of the mix and incubated with 10 mM N-acetyl-cysteine (NAC) (ACT 2
+ NAC), 100 μM genistein (ACT 2 + GEN), 10 ng/mL TNF-α or 1 μg/mL LPS alone, and with 10 ng/mL TNF-α or 1 μg/mL LPS incubated with 100 μM genistein (TNF-
α + GEN or LPS + GEN). DMSO-treated, unstimulated cells were used as the control (NACT). Additional control was used in the form of unstimulated cells treated
with 100 μM genistein (GEN). Intracellular ROS levels were examined by a CellROX Deep Red Reagent and confocal fluorescence microscopy. Nuclei were stained with
4’,6-diamidino-2-phenylindole (DAPI). Results representative of three independent experiments (with scale bars 25 μm) are shown. (B) Analysis of ROS were
additionally performed by fluorescent cell analyzer. The data are presented as the means ± standard deviation (SD) from three independent experiments. Significant
differences (p 0.05) between cell populations not expressing intracellular ROS (ROS [–]) and expressing intracellular ROS (ROS [+]) were observed for all tested
conditions, except for LPS where cell numbers of ROS (-) and ROS (+) were comparable. Most important, statistically significant differences of p 0.05 within ROS
groups are indicated with  for samples of TNF-α, TNF-α + GEN, and LPS versus NACT, with † for sample TNF-α + GEN with respect to TNF-α, while with ‡ for
sample LPS + GEN referred to LPS. Statistical analysis was performed using ANOVA with Tukey’s HSD test.
https://doi.org/10.1371/journal.pone.0192297.g005
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genistein have been safely used at high levels in several Asian populations in many centuries
and play a brilliant role in health promotion [44]. In this regards, we embarked on profound
research on the identification of the isoflavone genistein as a potential antipsoriatic compound
exerting potent anti-inflammatory effects by using an in vitro model of keratinocytes both nor-
mal and “psoriasis-like” types and at this phase of our work exhaustively testing genistein’s
effects in a mono-treated experimental design.
The main hallmarks of Ps are abnormally proliferating and differentiating keratinocytes;
therefore, each compound with the properties to reduce or normalize the increased prolifera-
tion and deregulated differentiation of psoriatic keratinocytes are strongly desired. In this
report, we showed in fact that genistein significantly affected proliferation of human keratino-
cytes, with non-toxic activity (S1 Fig and raw data in S1 Table, S2 Table). Accordingly, the
combination of the lack of cytotoxic and antiproliferative effects of genistein underlines the
value of this compound and indicates that it may be a useful antipsoriatic agent.
Large scale gene expression studies of the effects of genistein on keratinocyte transcrip-
tomes via microarray analysis revealed transcriptional changes that confirms known disease-
associated pathways and highlights genomic “hot spots” for DEGs (Fig 1A). These changes
included many psoriasis-related genes and were overlapped in multiple studies [1, 45]. We
observed a good level of concordance between our dataset and the results of previous studies,
as from 25% to 30% of dysregulated genes of keratinocytes treated with genistein for 24 and 48
hours, respectively, were present in the set of PRGwDE (Fig 1B). However, we detected the
limited consensus of app. 10% microarray datasets from analyses on shared HaCaT and HDFa
genes and PRGwDE transcripts, which may relate to more complex heterogeneity of subjects
across studies (S2 Fig). This was not astonishing, as a study employing RNA-seq (all on psori-
atic skin samples) also demonstrated the restricted consensus (with only 44% of their genes
overlapping with previous microarray studies) [46]. Interestingly, our results suggested that
aberrant expression of genes contributing to the progress of psoriasis could be improved by
the action of genistein. Modulation of their activities, by reducing the expression efficiency of
genes revealing enhanced activity in psoriatic cells and by stimulating the expression efficiency
of genes revealing decreased activity in psoriatic cells, was noted. Moreover, while assembling
and performing integration of our microarray data via enrichment, clustering, and correlation
analyses using specific bioinformatics tools dedicated to global perspective studies, we
observed a significant enrichment of functions and compartments involved in epidermal
homeostasis, but also pathways related to psoriasis condition (Figs 1C and 2; S3 Fig). We
detected clear modulation of psoriasis-associated transcripts levels after genistein treatment,
however at this time we hardly revealed pathways related to immunity and inflammatory acti-
vation. Exceptions were the pathways of the NOD-like receptor (NLR) signaling regulation
(Fig 2B and 2E) and Pathogenic Escherichia coli infection (Fig 2B, 2D and 2E), both compris-
ing genes down-regulated by genistein. These results are interesting in respect to the data
reported by Tervaniemi’s group [47], where the NLR signaling pathway, belonging to endoge-
nous cellular stress signals and pathogens recognized via pattern recognition receptors (PRRs),
with highly up-regulated transcripts was highlighted in psoriatic skin lesions. Besides, KEGG
Fig 6. Interleukin (IL)-8, IL-20, and IL-CCL2 production determined in HaCaT cells treated correspondingly with 100 μM
genistein (GEN), 1 μM methotrexate (MTX), proinflammatory “cytokine mix” at a concentration of 2 ng/mL in each compound of
the mix (ACT) and incubated with 100 μM genistein (ACT + GEN) or 1 μM methotrexate (ACT + MTX), 10 ng/mL tumor
necrosis factor-α (TNF-α) and incubated with 100 μM genistein (TNF-α + GEN) or 1 μM methotrexate (TNF-α + MTX), or 1 μg/
mL lipopolysaccharide (LPS) alone, and incubated with 100 μM genistein (LPS + GEN) or 1 μM methotrexate (LPS + MTX).
DMSO-treated, unstimulated cells were used as control (NACT). The data are presented as the means ± standard deviation (SD) from
three independent experiments. Comparisons among groups were performed using a one-way ANOVA with Tukey’s HSD test and
significant differences are marked with  for p 0.05 and with  for p 0.001.
https://doi.org/10.1371/journal.pone.0192297.g006
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pathway analyses performed in this work identified up-regulated genes that were enriched in
such function and cellular components as the lysosome (Fig 2A and 2C; I and K sections in S3
Fig). Cellular compartment terms, such as vesicle, endoplasmic reticulum, vacuole, Golgi
apparatus, and lysosomal lumen, were among the most significant clusters as well (Fig 1C–2).
This seems to be intriguing in light of our earlier research concerning the modulation of
expression of lysosomal metabolism by flavonoids, among them the phytoestrogen genistein
[29, 48]. On the other hand, one should mention that of all the components of the cell, the
lysosome is an obvious candidate for a role in the inflammatory process [49]. What is more,
modulation of the inflammatory response via lysosomal signaling and inflammasome-related
pathways was detected in human autoimmune-mediated inflammatory diseases [50], among
them in psoriasis (one of the most representative inflammatory skin disorder) [47, 51].
Both microarray and real-time qRT-PCR analyses indicated that genistein influences the
expression of numerous genes linked to psoriasis (Table 1). The altered expression signatures
point to stimulation of mainly the AMP-activated protein kinase (AMPK) signaling pathway
(known to limit inflammation) [52–54]), Fatty acid metabolism, Forkhead box O (FoxO) sig-
naling pathway, Tight junction and Longevity regulating pathway, while to inhibition of the
Cell division cycle and Metabolic signaling pathways as important targets for genistein (a can-
didate for psoriasis-inhibiting agent).
Despite the many controversies about the use of proper epidermal keratinocytes for in vitro
studies relevant to Ps, most often HaCaT cells (with mutant p53 and loss of p16ink4a) have
been employed as cellular models to investigate hyperproliferative skin diseases such as Ps and
to evaluate the antipsoriatic activities of tested molecules [12–16, 55]. HaCaT are often used
for psoriasis in vitro experiments instead of primary normal human epidermal keratinocytes
(NHEK) since the susceptibility of this cell line to treatment may change with the increasing
number of passages (whereas HaCaT cells provides an almost unlimited supply of identical
cells, assuring high reproducibility) [56]. Therefore, in this study a genistein-treated human
immortalized keratinocyte cell line HaCaT was utilized. In addition, for the development of a
somehow more appropriate model of human skin that closely mimics the processes leading to
psoriatic lesion formation, we evaluated the use of stimulated keratinocytes. As a result, we
found an approach with direct treatment of the keratinocytes with a “cytokine mix” as the clos-
est of the expected characteristics. The transcriptomic profiling with the use of real-time
qRT-PCR on “psoriasis-like” HaCaT cells treated with and without genistein (determined via
measurements with the use of panel 1) revealed significant alteration in the activity of most of
the tested psoriasis-related genes (Fig 3A and 3B). Moreover, expression profiling of selected
genes of inflammation-immune axis regulation (determined via measurements with the use of
panel 2) indicated important gene activity changes (Fig 3C and 3D). Interestingly, part of the
genes from these collections depicted in Fig 3A–3D were present among the transcripts regu-
lated in genistein-treated HaCaT included in Table 1.
To characterize further the mechanism underlying the anti-inflammatory effects of genis-
tein, we assessed the role of NF-κB signaling cascades in the “cytokine mix” and TNF-α-medi-
ated inflammatory responses present in keratinocytes exposed to the tested isoflavone.
Translocation of the NF-κB p65 subunit into the nucleus is an important step for its transcrip-
tional activity, which in turn seems to be mediated by PI3K signaling [57]. Previous work has
reported the importance of the PI3K pathway as an important regulator of growth and inflam-
mation in inflammation-mediated diseases such as psoriasis [58]. Moreover, studies indicated
that genistein, alone or even in combination with various pharmaceutical agents (e.g., selected
non-steroidal anti-inflammatory drugs), inhibits EGF receptor kinase and its downstream
effector PI3K, which in turn might also be implicated in NF-κB transcriptional activation [59,
60]. Thus, to test these correlations, we primarily examined the activity of PI3K. Our
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experiments revealed no statistically significant differences in the activity of this kinase in kera-
tinocytes stimulated with the cytokine cocktail versus the unstimulated one, similarly with no
effect of genistein on this phenomenon (S5 Table). Interestingly, at the same time, we found
modulation of PI3K gene expression in such conditions (S5 Table). Furthermore, genistein
prevented “cytokine mix” as well as TNF-α-induced NF-κB translocation (Fig 4; S4 Fig). Thus,
we conclude at lack of PI3K pathway involvement in NF-κB activation in our experimental
design, which is not surprising, as it seems to be a cell- and tissue-specific event [61]. Our
results regarding intracellular ROS accumulation showed that stimulation of keratinocytes
with TNF-α and LPS, but surprisingly not with the “cytokine mix”, increases ROS levels,
which on the other hand was effectively reduced by genistein (Fig 5). These data indicated that
the tested isoflavone could attenuate TNF-α- and LPS-induced inflammatory responses in
HaCaT by suppressing ROS activation. This is consistent with the antioxidant properties of
genistein and reports of others, where this agent has been shown to protect cells against ROS
by scavenging free radicals, enhancing activity of antioxidant enzymes and reducing produc-
tion of hydrogen peroxide [62]. Our results are also corroborated by the research report of
Young’s group, which has documented that ROS are involved in TNF-α-mediated signaling
pathways associated with inflammatory skin disease such as psoriasis via TNF-α-dependent
NF-κB activation [61]. After all, to further investigate the anti-inflammatory activity of genis-
tein, we examined the expression of selected inflammatory mediators once the cells exposed or
not exposed to genistein were stimulated either with the cytokine cocktail, TNF-α, or LPS (Fig
6 and raw data in S7 Table). We found that, regardless of the type of cell activation used, the
levels of three (IL-8, IL-20 and CCL2) out of five cytokines tested were decreased in the kerati-
nocyte supernatant in response to the isoflavone. It is worth emphasizing, too, that the same
trend (i.e., first an increased expression in response to stimulation, followed by reduction after
genistein treatment) was observed in both RNA and protein levels of these three cytokines
(Figs 3C [the forth cluster] and 6). Based on these results, we conclude that genistein may sup-
press inflammatory cytokine production, at least partly, by inhibiting the ROS/NF-κB pathway
in activated HaCaT cells. We, thus, hypothesize that genistein attenuates ROS-mediated NF-
κB activation and subsequent inflammatory cytokine production in “psoriasis-like” keratino-
cytes. These data provide new insight into the anti-inflammatory mechanism and antipsoriatic
activity of genistein, giving scientific support for its use in the treatment of Ps.
Our work exploits and expands on recent breakthroughs in the understanding of cellular
cross-talk to develop novel therapeutic approaches based on the use of the isoflavone genistein
to treat complex diseases such as psoriasis. It is believed that investigations presented in this
report can provide new information regarding the molecular mechanism of the action of
genistein modulating the activity of genes deregulated in the cells of people suffering from pso-
riatic skin disease, at the same time significantly affecting the signaling pathways in such cells.
Understanding of these issues may result in serious progress in therapeutic approaches, where,
as it is nowadays increasingly observed, combination therapy rather than monotherapy are
more effective. Indeed, monotherapy with systemic agents is effective for many patients with
Ps; however, some of them require combination approaches. Perhaps the use of genistein in
such therapy with, for example, biologic drugs may have an even more beneficial outcome
than being used alone. Main aspects in considering a switch from monotherapy to combina-
tion treatment are less cumulative and/or acute toxicity, fewer side effects, and obviously
improved therapeutic outcomes for the latter. The research on the identification of the isofla-
vone genistein as a potential antipsoriatic compound exerting potent anti-inflammatory
effects, together with anti-Ps systemic drugs with complementary activities may be worth the
attention. Because of the safety of genistein [44], its use might be recommended as adjuvant
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together with other agents such as biological drugs in psoriasis management, especially while
handling patients resistant to treatment.
In this study, we report the range of knowledge gained with the in vitro cell culture in form
of keratinocytes that closely mimic the psoriatic state and on genistein used alone. The
obtained results are intended to be utilized in the next phase of research involving animal
models, and also the combination approach of the isoflavone genistein and selected systemic
drugs. Because investigations of other groups supported our commentary on the potential
administration of soybeans as a potential weapon in the armamentarium against psoriasis, it is
believed that this paper should serve to encourage us and other researchers to conduct further
studies on this subject.
Supporting information
S1 Fig. Effect of genistein on the viability of HaCaT measured by the level of MTT incorpo-
rated into cells. Keratinocytes were treated with different concentrations of genistein for 24
hours, 48 hours (cytotoxicity assay), and 7 days (proliferation assay); afterward the percentage
of cell survival was determined. Results are expressed as mean values of three experiments
with error bars indicating standard deviation.
(TIF)
S2 Fig. Venn diagrams summarizing the number of deregulated genes of whole genome of
HaCaT, HDFa treated with 100 μM genistein for 24 hours or PRGwDE compared to the
respective untreated conditions.
(TIF)
S3 Fig. Results of annotation enrichment analysis. Terms identified in the GSEA for corre-
lated genes in the categories: “Biological Processes”, “Molecular Functions” and “Cell Com-
partments” with up to 30 gene sets, enriched among those up- (A, C, E, G, I, K) and down-
regulated (B, D, F, H, J, L) by 100 μM genistein 24 hours (A, B, E, F, I, J) and 48 hours (C, D,
G, H, K, L) after treatment in HaCaT cells (Size, number of genes in each set; NES, normalized
enrichment score; FDR q-val, q-value of false discovery rate). GSEA was performed using the
microarray data to design a so-called psoriasis gene expression profile between keratinocytes
treated with or without genistein. Tables A–D illustrate up to 30 top “Biological Processes”
from 83 up-regulated and 27 down-regulated genes, after 24 hours of treatment with genistein
and from 113 up-regulated and 77 down-regulated genes, after 48 hours of treatment with
genistein. Tables E–H illustrate the top 30 “Molecular Functions” from 77 up-regulated and
168 down-regulated genes, after 24 hours of treatment and from 160 up-regulated and 90
down-regulated genes, respectively, after 48 hours of treatment with genistein. Tables I–L illus-
trate the top 30 “Cell Compartments” from 56 up-regulated and 136 down-regulated, after 24
hours of treatment and from 112 up-regulated and 111 down-regulated, respectively, after 48
hours of treatment with genistein. All were enriched among the leading edge gene subsets,
with p-value< 0.01 and FDR 0.25.
(PDF)
S4 Fig. Effect of genistein on NF-κB p65 subunit induction. Keratinocytes were pretreated
with or without 100 μM genistein (GEN) for 2 hours, and then incubated with a proinflamma-
tory “cytokine mix” (ACT) or only TNF-α (10 ng/mL) (TNF-α + GEN), for 30 minutes. Only
DMSO-treated, unstimulated cells were used as control (NACT). Nuclear translocation of the
NF-κB p65 subunit was assessed by indirect immunofluorescence confocal microscopy using
anti-p65 subunit antibodies and appropriate fluorescently tagged secondary antibodies. Nuclei
were stained with 4’,6-diamidino-2-phenylindole (DAPI). Results representative of three
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independent experiments (with scale bars 100 μm) are shown.
(TIF)
S1 Table. (Raw data of S1 Fig) Effect of genistein on the viability of HaCaT measured by
the level of MTT incorporated into cells. Keratinocytes were treated with different concen-
trations of genistein (GEN) for 24 hours, 48 hours (cytotoxicity assay), and 7 days (prolifera-
tion assay); afterward the percentage of cell survival was determined. Results are expressed as
mean values of three experiments with error bars indicating standard deviation.
(DOCX)
S2 Table. LC (cytotoxicity assay) and IC (proliferation assay) index values of genistein in
keratinocyte-based assay. Cytotoxicity is expressed as LC25, 50 or 75 (i.e., concentration of
the tested drug [μM]) that is lethal to 25%, 50%, or 75% of HaCaT cells, respectively, in a cul-
ture exposed to the drug for 24 and 48 hours. Antiproliferative activity is expressed as IC25, 50
or 75 (i.e., concentration of the tested drug [μM]) that causes 25%, 50%, or 75% inhibition of
keratinocyte proliferation, respectively, in a culture exposed to the drug for 7 days.
(DOCX)
S3 Table. Descriptive statistics of 10 candidate housekeeping genes (HKG) based on their
crossing point (CP) values. Abbreviations: n: number of samples; GM [CP]: the geometric
mean of CP; AM [CP]: the arithmetic mean of CP; Min [CP] and Max [CP]: the extreme values
of CP; SD [± CP]: the standard deviation of the CP; CV [% CP]: the coefficient of variance
expressed as a percentage on the CP level; Min [x-fold] and Max [x-fold]: the extreme values of
expression levels expressed as an absolute x-fold over- or under-regulation coefficient; SD [±
x-fold]: standard deviation of the absolute regulation coefficients; coeff. of corr. [r]: coefficient
of correlation; coeff. of det. [r2]: coefficient of determination.
(DOCX)
S4 Table. Expression patterns of keratinocyte differentiation markers KRT10 and LOR,
and inflammation markers S100A7 and S100A9. The analysis was made via real-time
qRT-PCR in response to various tested “psoriasis-like” activation processes: treatment with
the proinflammatory “cytokine mix” (2 ng/mL of IL-1A, IL-17A, IL-22, OSM and TNF-α), co-
culture of HaCaT and THP-1, with or without addition of 1 μg/mL lipopolysaccharide (LPS)
for 24 hours. mRNA expression levels for the four marker genes were normalized using TBP
housekeeping reference and expressed as the fold change for stimulated vs. unstimulated cells.
(DOCX)
S5 Table. Activity of PI3 kinase and PI3K gene in HaCaT. Keratinocytes were treated with
0.05% DMSO only (NACT), stimulated with a combination of proinflammatory “cytokine
mix” (ACT), stimulated with a combination of proinflammatory “cytokine mix” and treated
with 100 μM genistein (GEN), or stimulated with a combination of proinflammatory “cytokine
mix” and treated with wortmannin (a PI3K inhibitor) (WORT).
(DOCX)
S6 Table. (Raw data of Fig 5(B)) attenuation of the level of reactive oxygen species (ROS)
by genistein. (B) Analysis of ROS were additionally performed by fluorescent cell analyzer.
The data are presented as the means ± standard deviation (SD) from three independent experi-
ments. Significant differences (p 0.05) between cell populations not expressing intracellular
ROS (ROS [–]) and expressing intracellular ROS (ROS [+]) were observed for all tested condi-
tions, except for LPS where cell numbers of ROS (-) and ROS (+) were comparable. Statistical
analysis was performed using ANOVA with Tukey’s HSD test.
(DOCX)
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S7 Table. (Raw data of Fig 6) interleukin (IL)-8, IL-20, and CCL2 production determined
in HaCaT cells treated correspondingly with 100 μM genistein (GEN), 1 μM methotrexate
(MTX), proinflammatory “cytokine mix” at a concentration of 2 ng/mL in each compound
of the mix (ACT) and incubated with 100 μM genistein (ACT + GEN) or 1 μM methotrex-
ate (ACT + MTX), 10 ng/mL tumor necrosis factor-α (TNF-α) and incubated with 100 μM
genistein (TNF-α + GEN) or 1 μM methotrexate (TNF-α + MTX), or 1 μg/mL lipopolysac-
charide (LPS) alone, and incubated with 100 μM genistein (LPS + GEN) or 1 μM metho-
trexate (LPS + MTX). DMSO-treated, unstimulated cells were used as control (NACT). The
data are presented as the means ± standard deviation (SD) from three independent experi-
ments. Comparisons among groups were performed using a one-way ANOVA with Tukey’s
HSD test.
(DOCX)
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